OM
RPTX

Opaleye Management’s Repare Therapeutics RPTX Stock Holding History

Opaleye Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-67,561
Closed -$318K – 59
2024
Q1 		$318K Buy
+67,561
New +$433K 0.07% 52
2022
Q2 		– Sell
-55,678
Closed -$793K – 52
2022
Q1 		$793K Buy
+55,678
New +$826K 0.25% 42

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management's RPTX Position: Q2 2024 in Review

Opaleye Management sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 67,561 shares — an estimated $318K sold.

Opaleye Management first reported a position in RPTX in Q1 2022 and held it in 2 quarters. The position peaked at $793K in Q1 2022. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

  • Opaleye Management reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Opaleye Management sold 67,561 Repare Therapeutics shares in Q2 2024, an estimated $318K.
  • Opaleye Management first reported a position in Repare Therapeutics in Q1 2022 and held it in 2 quarters.
  • Opaleye Management's Repare Therapeutics position peaked at $793K in Q1 2022.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.